CervoMed Inc CRVO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- $2.89
- Day Range
- $2.82–2.92
- 52-Week Range
- $2.18–13.09
- Bid/Ask
- $2.82 / $2.87
- Shares Outstanding
- 13.53M
- Market Cap
- $26.16M
- Volume/Avg
- 216,242 / 6M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 15
- Website
- https://www.cervomed.com
Valuation
|
Metric
|
CRVO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.52 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
CRVO
Financial Strength
|
Metric
|
CRVO
|
|---|---|
Quick Ratio | 2.87 |
Current Ratio | 3.36 |
Interest Coverage | — |
Quick Ratio
CRVO
Profitability
|
Metric
|
CRVO
|
|---|---|
Return on Assets (Normalized) | −98.44% |
Return on Equity (Normalized) | −116.33% |
Return on Invested Capital (Normalized) | −120.70% |
Return on Assets
CRVO
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|#bctTT | LOCK|#%jBN | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|VQ$fFTB | LOCK|CN<>g | $71B | |||
| argenx SE ADR
ARGX
| LOCK|!SbHk$$ | LOCK|n!^ | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|Y$%^j? | LOCK|x@Q | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|v%yP?T | LOCK|#@<j% | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|Stf#QxN$ | LOCK|Dp&j | $26B | |||
| Moderna Inc
MRNA
| LOCK|!cgFpCH | LOCK|&Fp | $24B | |||
| Incyte Corp
INCY
| LOCK|hvngc! | LOCK|^v$ | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|&dqHfkW | LOCK|Q#T | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|b&lHhvB | LOCK|^t | $16B |
United States